RELIEF Therapeutics Holding AG (OTCMKTS: RLFTF) Says Its Collaboration Partner Has Validated a Commercial Aviptadil Formulation

July 26, 2021

RELIEF Therapeutics Holding AG (OTCMKTS: RLFTF) has announced that the parent company of its US partner NRx Pharmaceuticals Inc. (NASDAQ: NRX) has confirmed the validation of a commercial aviptadil formulation for intravenous use. This will allow for high volume production with an expected one year or more stability under the ideal storage condition. NRx successfully validates new aviptadil formulation  NRx CEO Jonathan Javitt said, “When we began developing aviptadil for…

Read More >>